Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3473 in adult primary immune thrombocytopenia
NCT06900920Phase 3Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB3473 in primary immune thrombocytopenia (ITP), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2025; status: recruiting.
02
Drugs
TQB3473
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06900920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900920.